Immunome (IMNM) Stock Forecast & Price Target

Immunome is focused on developing first-in-class targeted oncology therapies, with a pipeline that includes varegacestat, an investigational oral gamma secretase inhibitor that has reported positive topline results in a Phase 3 trial for desmoid tumors. The company is also developing a ROR1-targeted antibody-drug conjugate, called IM-1021, which has shown objective responses in multiple dose levels. Immunome's diverse pipeline, led by experienced executives in the field of ADCs, positions the company to potentially become a major player in the next generation of targeted cancer therapeutics.

Immunome is a preclinical biotechnology company focused on developing targeted oncology therapies; however, their outlook is negative due to concerns about the efficacy of their treatments targeting ROR1, which has not been confirmed as a viable oncogene or essential for cancer cell viability. Additionally, there are questions about antigen escape as a potential limitation for ROR1-targeting ADCs. The company has high R&D expenses and a significant cash position, but their pipeline updates have not shown strong results in solid tumors.